Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Looks Beyond Biosimilars Via Takeda Tie-Up

Executive Summary

Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.

Advertisement

Related Content

SCM Lifescience CEO On Developing High Purity, Disease-Specific Stem Cell Therapies
Celltrion Taps New Contract Business As Route To Novel Drugs
Celltrion Taps New Contract Business As Route To Novel Drugs
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Deal Watch: Takeda Continues Transaction Spree With Four More Deals
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Interview: Setting The Course For Takeda’s R&D Future
EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira
Samsung Enters Oncology as Trastuzumab Accepted For EU Review
Samsung Bioepis's Etanercept Biosimilar To Be Rolled Out In Europe

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel